To amend the Public Health Service Act to update quality standards for mammography facilities for the use of AI systems, and for other purposes.

1) What happened and its current status: On April 27, 2026, Representative David Schweikert (R-AZ) introduced HR8526 in the 119th Congress. The bill was immediately referred to the House Committee on Energy and Commerce — the primary committee of jurisdiction for FDA-related and Medicare-related healthcare quality legislation. This is an early-stage bill with three recorded actions (introduction, referral). It has not yet received a committee hearing or markup. 2) The money trail — authorization vs appropriation: HR8526 does not authorize or appropriate any direct federal spending. Instead, it creates a regulatory mandate under existing MQSA authority, forcing private-sector compliance investment. The cost burden falls on mammography facilities (hospitals, imaging centers, breast clinics) to purchase or license FDA-cleared AI software. The economic mechanism is NOT government spending — it is a compliance-driven procurement cycle. Industry estimates for AI mammography software per facility range from $50,000-$250,000 (one-time integration + annual licensing), putting the total addressable market for this regulatory change at roughly $400M-$2.2B over a 3-5 year compliance window. 3) Structural winners and losers: The direct winner is $GEHC — GE HealthCare commands ~25-30% of the U.S. mammography market with its Senographe Pristina system and AI-powered analytics. Other beneficiaries include $HOLX (Hologic — 3D mammography and AI software) and $SIEM (Siemens Healthineers — mammography and AI), though these are non-U.S. or less directly tied. Outsized impact on $GEHC given its U.S. installed base and recent stock decline to ~$60 (near 52-week low). No significant losers identified — this is an adoption mandate, not a restriction. 4) Real market data analysis: $GEHC is trading at $59.96 as of April 30, 2026, with a 52-week range of $58.75-$89.77. The stock has declined -12.89% in the past 7 days and -15.76% over the past 30 days. Notably, the price dropped from $70.48 on April 27 (the date of bill introduction) to $59.96 on April 30 — a -14.9% decline over 3 trading days. This price action appears correlated with broader market weakness (potentially unrelated to this bill) but creates a potential entry point at near-52-week lows if the bill gains legislative traction. 5) Timeline — legislative steps remaining: The bill must: (a) receive a hearing in Energy and Commerce Subcommittee on Health, (b) pass committee markup, (c) pass House floor vote, (d) pass Senate companion (none yet introduced), (e) be signed by President. Given early stage and single sponsor (junior House member), realistic passage window is 12-24 months if at all. However, bipartisan interest in AI healthcare tools (AI in Medicare covered in other 2025-2026 legislation) moderately elevates odds.